SANTA CRUZ BIOTECHNOLOGY, INC.

LRRFIP1 (N-16): sc-66682



BACKGROUND

LRRFIP1 is an 738 amino acid human protein whose rodent counterpart is known as Lrrfip1. LRRFIP1 is a transcriptional repressor which will preferentially bind to the GC-rich consensus sequence (5'-AGCCCCCGGCG-3') and may also regulate expression of TNF, EGFR and PDGF-A. LRRFIP1 is also believed to control smooth muscle cell proliferation following arterial injury through PDGF-A repression. The N-terminus of LRRFIP1 shows high homology to the coiled-coil domain of FLAP, a protein which binds the leucine-rich repeat (LRR) of Flightless I, and the interaction of LRRFIP1 with the LRR of Flightless I has been confirmed. LRRFIP1 does not bind single-stranded DNA or RNA significantly and binds double-stranded DNA weakly. In contrast, LRRFIP1 binds double-stranded RNA with high affinity, and two molecules of LRRFIP1 bind the TaR stem. The RNA binding domain has been identified and encompasses a lysine-rich motif. Flightless I has a C-terminal TaR-like domain which binds actin and therefore the association of LRRFIP1 with the LRR of Flightless I may provide a link between the actin cytoskeleton and RNA in mammalian cells.

CHROMOSOMAL LOCATION

Genetic locus: LRRFIP1 (human) mapping to 2q37.3.

SOURCE

LRRFIP1 (N-16) is an affinity purified goat polyclonal antibody raised against a peptide mapping at the N-terminus of LRRFIP1 of human origin.

PRODUCT

Each vial contains 200 μ g lgG in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin. Also available as TransCruz reagent for Gel Supershift and ChIP applications, sc-66682 X, 200 μ g/0.1 ml.

Blocking peptide available for competition studies, sc-66682 P, (100 μ g peptide in 0.5 ml PBS containing < 0.1% sodium azide and 0.2% BSA).

APPLICATIONS

LRRFIP1 (N-16) is recommended for detection of LRRFIP1 of human origin by Western Blotting (starting dilution 1:200, dilution range 1:100-1:1000), immunoprecipitation [1-2 µg per 100-500 µg of total protein (1 ml of cell lysate)], immunofluorescence (starting dilution 1:50, dilution range 1:50-1:500) and solid phase ELISA (starting dilution 1:30, dilution range 1:30-1:3000).

Suitable for use as control antibody for GCF2 siRNA (h): sc-63161, GCF2 shRNA Plasmid (h): sc-63161-SH and GCF2 shRNA (h) Lentiviral Particles: sc-63161-V.

LRRFIP1 (N-16) X TransCruz antibody is recommended for Gel Supershift and ChIP applications.


Molecular Weight of LRRFIP1 isoforms: 85/120/160 kDa.


Positive Controls: HeLa whole cell lysate: sc-2200, Jurkat whole cell lysate: sc-2204 or LRRFIP1 (h4): 293T Lysate: sc-177275.

RECOMMENDED SECONDARY REAGENTS

To ensure optimal results, the following support (secondary) reagents are recommended: 1) Western Blotting: use donkey anti-goat IgG-HRP: sc-2020 (dilution range: 1:2000-1:100,000) or Cruz Marker[™] compatible donkey anti-goat IgG-HRP: sc-2033 (dilution range: 1:2000-1:5000), Cruz Marker[™] Molecular Weight Standards: sc-2035, TBS Blotto A Blocking Reagent: sc-2333 and Western Blotting Luminol Reagent: sc-2048. 2) Immunoprecipitation: use Protein A/G PLUS-Agarose: sc-2003 (0.5 ml agarose/2.0 ml). 3) Immunofluorescence: use donkey anti-goat IgG-FITC: sc-2024 (dilution range: 1:100-1:400) or donkey anti-goat IgG-TR: sc-2783 (dilution range: 1:100-1:400) with UltraCruz[™] Mounting Medium: sc-24941.

DATA





LRRFIP1 (N-16): sc-66682. Western blot analysis of LRRFIP1 expression in HeLa $({\bm A})$ and Jurkat $({\bm B})$ whole cell lysates.

LRRFIP1 (N-16): sc-66682. Western blot analysis of LRRFIP1 expression in non-transfected: sc-117752 (A) and human LRRFIP1 transfected: sc-177275 (B) 293T whole cell lysates.

STORAGE

Store at 4° C, **DO NOT FREEZE**. Stable for one year from the date of shipment. Non-hazardous. No MSDS required.

RESEARCH USE

For research use only, not for use in diagnostic procedures.

PROTOCOLS

See our web site at www.scbt.com or our catalog for detailed protocols and support products.

MONOS Satisfation Guaranteed

Try LRRFIP1 (G-4): sc-514221 or LRRFIP1 (C-3): sc-398240, our highly recommended monoclonal alternatives to LRRFIP1 (N-16).